FDA approves Treanda (bendamustine hydrochloride) for non-Hodgkin’s lymphoma

Patients with B-cell non-Hodgkin’s lymphoma (NHL) who have been treated with rituximab but whose lymphoma still progresses, may have hope with another treatment called Treanda (bendamustine hydrochloride). Indolent lymphoma, or lymphoma that resists treatment, is difficult to treat and is not currently curable. Treanda, while not a cure, may help slow down its progress.

The United States FDA had already approved use of Treanda for the treatment of chronic lymphocytic leukemia (CLL). CLL is the most common form of leukemia in the United States.

~~~~

Tags: cancer blog, lymphoma, non hodgkin’s lymphoma, treanda, bendamustine